Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
65 hedge funds and large institutions have $5.31M invested in Unity Biotechnology in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 14 closing their positions.
3,076% more call options, than puts
Call options by funds: $1.05M | Put options by funds: $33K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 17
0.47% less ownership
Funds ownership: 1.83% → 1.36% (-0.47%)
7% less funds holding
Funds holding: 70 → 65 (-5)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
63% less capital invested
Capital invested by funds: $14.2M → $5.31M (-$8.85M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$131K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$72.3K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$53.7K |
| 4 |
Renaissance Technologies
New York
|
+$42.5K |
| 5 |
Charles Schwab
San Francisco,
California
|
+$38.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$1.02M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.01M |
| 3 |
Millennium Management
New York
|
-$351K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$119K |
| 5 |
Two Sigma Advisers
New York
|
-$106K |
UBX Hedge Fund Activity: Q2 2022 in Review
65 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q2 2022, worth a combined $5.31M — down 63% from $14.2M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of UBX and 9 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 17 added.
The largest buyer was Vanguard Group, adding an estimated $131K. The largest seller was Pura Vida Investments, cutting an estimated $1.02M.
- 65 institutional investors held Unity Biotechnology (UBX) as of Q2 2022, down from 70 in Q1 2022.
- Funds reported $5.31M of Unity Biotechnology stock for Q2 2022, down 63% quarter-over-quarter.
- 9 funds opened new Unity Biotechnology positions in Q2 2022 and 14 closed out, a net change of -5 holders.
- The largest Unity Biotechnology buyer in Q2 2022 was Vanguard Group, an estimated $131K added.
- The largest Unity Biotechnology seller in Q2 2022 was Pura Vida Investments, an estimated $1.02M sold.
Based on aggregated 13F filings for Q2 2022.